Patents by Inventor Matthew R. Kaller

Matthew R. Kaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazole agonists of the APJ receptor
    Patent number: 9573936
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: February 21, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042897
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 16, 2017
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042871
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 16, 2017
    Inventors: Ning Chen, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170044131
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 16, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042872
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 16, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua Ma, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. Judd, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170035744
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170037026
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 9, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20160340336
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: May 18, 2016
    Publication date: November 24, 2016
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Azetidine and piperidine compounds useful as PDE10 inhibitors
    Patent number: 9493459
    Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: November 15, 2016
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Jian J. Chen, Michael J. Frohn, Matthew R. Kaller, Qingyian Liu, Thomas T. Nguyen, Alexander J. Pickrell, Wenyuan Qian, Robert M. Rzasa, Wenge Zhong
  • Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
    Patent number: 9376450
    Abstract: Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: June 28, 2016
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Holger Monenschein, Thomas T. Nguyen, Andreas Reichelt, Robert M. Rzasa
  • AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS
    Publication number: 20160176874
    Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Inventors: Jennifer R. ALLEN, Jian J. CHEN, Michael J. FROHN, Matthew R. KALLER, Qingyian LIU, Thomas T. NGUYEN, Alexander J. PICKRELL, Wenyuan QIAN, Robert M. RZASA, Wenge ZHONG
  • Azetidine and piperidine compounds useful as PDE10 inhibitors
    Patent number: 9303028
    Abstract: Azetidine and piperidine compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: April 5, 2016
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Jian J. Chen, Michael J. Frohn, Matthew R. Kaller, Qingyian Liu, Thomas T. Nguyen, Alexander J. Pickrell, Wenyuan Qian, Robert M. Rzasa, Wenge Zhong
  • TRPM8 antagonists and their use in treatments
    Patent number: 9096527
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: August 4, 2015
    Assignee: AMGEN INC.
    Inventors: Kaustav Biswas, James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Vu Van Ma, Holger Monenschein, Thomas T. Nguyen, David J. St. Jean, Jr., Chester Chenguang Yuan, Wenge Zhong
  • Chroman derivatives as TRPM8 inhibitors
    Patent number: 8952009
    Abstract: Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: February 10, 2015
    Assignee: Amgen Inc.
    Inventors: Kaustav Biswas, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Vu Van Ma, Kelvin Sham, Wenge Zhong
  • CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
    Publication number: 20150031668
    Abstract: Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 29, 2015
    Inventors: Kaustav Biswas, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Vu Van Ma, Kelvin Sham, James Brown, Wenge Zhong, Thomas T. Nguyen
  • TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
    Publication number: 20140235642
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: AMGEN INC.
    Inventors: James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Holger Monenschein, Thomas T. Nguyen, Nobuko Nishimura, Wenge Zhong
  • TRPM8 antagonists and their use in treatments
    Patent number: 8778941
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: July 15, 2014
    Assignee: AMGEN Inc.
    Inventors: James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Holger Monenschein, Thomas T. Nguyen, Nobuko Nishimura, Wenge Zhong
  • Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
    Patent number: 8759532
    Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: June 24, 2014
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Kaustav Biswas, Frank Chavez, Jr., Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Home, Essa Hu Harrington, Matthew R. Kaller, Roxanne K. Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
  • TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
    Publication number: 20140171639
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: AMGEN INC.
    Inventors: Kaustav Biswas, James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Vu Van Ma, Holger Monenschein, Thomas T. Nguyen, David J. St. Jean, JR., Chester Chenguang Yuan, Wenge Zhong
  • TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
    Publication number: 20140171406
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: AMGEN INC.
    Inventors: Kaustav Biswas, James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Vu Van Ma, Holger Monenschein, Thomas T. Nguyen, David J. St. Jean, JR., Chester Chenguang Yuan, Wenge Zhong